Secondary Logo

Journal Logo

You can read the full text of this article if you:

Access through Ovid
REVIEWS

Which antidepressants have demonstrated superior efficacy? A review of the evidence

Montgomery, Stuart A.a; Baldwin, David S.b; Blier, Pierref; Fineberg, Naomi A.c; Kasper, Siegfriedh; Lader, Malcolmd; Lam, Raymond W.g; Lépine, Jean-Pierrei; Möller, Hans-Jürgenk; Nutt, David J.e; Rouillon, Fredericj; Schatzberg, Alan F.l; Thase, Michael E.m

Author Information
International Clinical Psychopharmacology: November 2007 - Volume 22 - Issue 6 - p 323-329
doi: 10.1097/YIC.0b013e3282eff7e0

Abstract

Erratum

A typographical error was published in the review ‘Which antidepressants have demonstrated superior efficacy? A review of the evidence’ by (Montgomery et al. []) which appeared in 323–329 of International Clinical Psychopharmacology, Volume 22, issue 6.

The following declaration of research grants, equity and/or honoraria for lectures or for acting as consultants to pharmaceutical companies should have appeared in the conflict of interest statement in the acknowledgement section of the article.

Alan F. Schatzberg – Abbott, Corcept, Eli Lilly, Forest Labs, GlaxoSmithKline, Lundbeck, Merck, Neurocrine, Neuronetics, Novartis, Pathway Diagnostics, Pfizer, Quintiles, Somaxon, Somerset, Wyeth; named inventor on pharmacogenetic use patents on prediction of antidepressant response.

International Clinical Psychopharmacology. 23(1):61, January 2008.

© 2007 Lippincott Williams & Wilkins, Inc.